At the news
? BULLISHIMPACT 7/10 8-K filed Apr 17, 2026 at 15:11 ET
Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing that its investigational WEE1 inhibitor azenosertib demonstrates strong antitumor activity in triple-negative breast cancer (TNBC), including complete responses in ADC-resistant models. The company also presented real-world evidence confirming poor outcomes for Cyclin E1-positive ovarian cancer patients, reinforcing the unmet need for azenosertib in this population.
- Azenosertib combinations induced complete tumor responses in 7 of 8 mice (87.5%) in a TNBC model resistant to sacituzumab govitecan
- Prevented tumor progression in 8 of 8 mice for over 52 days vs. 100% progression within 30 days with enfortumab vedotin alone
- Azenosertib monotherapy showed 42-99% tumor growth inhibition across 12 TNBC models
- Cyclin E1-positive ovarian cancer patients had significantly worse outcomes: 13.2-14.9 months time to next treatment vs. 19.5 months for Cyclin E1-negative patients (p<0.002)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access